US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

OmniAb, Inc. - Common Stock (NQ:OABI)

4.870 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OmniAb, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
OmniAb to Host Investor & Analyst Day on October 6, 2026
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb to Participate in Upcoming Investor Conferences
From OmniAb, Inc.
Via Business Wire
OmniAb (NASDAQ:OABI) Passes Minervini Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
OmniAb (NASDAQ:OABI) Beats Q2 Estimates and Raises Full-Year Guidance ↗
Via Chartmill
OmniAb (NASDAQ:OABI) Surges on Q1 Beat and Raised 2026 Guidance ↗
Via Chartmill
OmniAb Inc (NASDAQ:OABI) Reports Q4 and Full-Year 2025 Earnings Miss, Provides 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
OmniAb Raises 2026 Financial Guidance
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb (OABI) Q2 2026 Earnings Call Transcript ↗
Clinical programs advance as OmniAb raises full-year revenue guidance to $32M-$36M. 
Via The Motley Fool
Topics Earnings
News headline image
OmniAb Q2 Earnings Call Highlights ↗
OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and... 
Via MarketBeat
Topics Earnings
News headline image
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
Via Investor Brand Network
News headline image
OmniAb to Report Second Quarter 2026 Financial Results on August 6
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb Names Amechi Nwachuku Chief Operating Officer
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb (OABI) Q1 2026 Earnings Transcript ↗
OmniAb (OABI) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
OmniAb Q1 Earnings Call Highlights ↗
OmniAb (NASDAQ:OABI) reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and... 
Via MarketBeat
Topics Earnings
News headline image
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb to Participate in Three Upcoming Investor Conferences
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb to Report First Quarter 2026 Financial Results on May 7
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb (OABI) Q4 2025 Earnings Call Transcript ↗
OmniAb (OABI) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb to Participate at the Leerink Partners Global Healthcare Conference
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
From OmniAb, Inc.
Via Business Wire
News headline image
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb to Hold OmniUltra Virtual Investor Event on December 15
From OmniAb, Inc.
Via Business Wire
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
From OmniAb, Inc.
Via Business Wire
News headline image
OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >